Science

Pipeline

Four R&D Programs based on BAPAI Platform:

  1.  Clinical Development of First-in-Class firibastat, the first drug candidate in the BAPAI class, for the treatment of high blood pressure
  2. Development of therapeutic combinations involving a BAPAI with another antihypertensive drug
  3. Optimization of BAPAI products and development of a “Best-in-Class” product
  4. Development of firibastat product for the treatment of heart failure
Projects progress

Projects progress

Firibastat

First-in-class : Treatment as monotherapy

QGC011

Hypertension in combination

QGC006

Best-in-class: Optimized treatment of hypertension as monotherapy

Firibastat

First-in-class : Heart failure